Dublin, Ireland – 3 December 2020: Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that it has licensed the Chinese rights for Lumeblue™ to China Medical System Holdings Ltd. (“CMS”) (SEHK: 867).
Cosmo Technology's Methylthioninium chloride Cosmo ( Methylthioninium chloride) Receives Approval In Europe
Cosmo Pharmaceuticals NV (SIX: COPN) today announced that the European Commission (EC) has approved Methylthioninium Chloride Cosmo, prolonged release tablets (Methylene Blue MMX) for the visualization of colorectal lesions during colonoscopies. This is the first approval of Methylene Blue MMX and is also the first time an oral drug has been approved to improve the outcome of colonoscopies. The Centralized European licence will be effective simultaneously in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.
Enforcement Report - Week of August 15, 2018
Laboratoire Atlas Inc. Recalls Atlas methylene blue solution 1%
Keneric Healthcare, a medical device company that offers innovative and cost effective patient care products, today announced their partnership with Angelini Pharma Inc. This partnership will expand the reach of both companies by leveraging their clinical advocates, market share and areas of expertise.
Provepharm`s Provayblue(Methylene Blue) approved in US for methemoglobinemia
Drug shortages become issue in Teva and Mylan hook-up
Daiichi Sankyo Launches Methemoglobinemia Treatment Methylene Blue Injection 50mg